Ibrutinib combination regimens for CLL from ASH 2017

Despite the combination of ibrutinib and rituximab not significantly affecting progression-free survival in patients with chronic lymphocytic leukemia (CLL), many groups are testing ibrutinib combinat... Author: VJHemOnc Added: 01/08/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts